FDA Warning To Skin-Care Firm Shows Perils Of Cosmetics-To-Drug Transition
This article was originally published in The Rose Sheet
Executive Summary
FDA's warning letter to skin-care product firm MW Laboratories for marketing unapproved new drugs illustrates the potentially perilous transition from marketing cosmeceuticals to making OTC claims
You may also be interested in...
FDA Warns JabaLabs About Drug Claims For Anti-Aging Cosmetics
An FDA warning letter to San Antonio, Texas-based skin-care marketer JabaLabs, LLC signals that the agency is continuing its efforts to crack down on overreaching marketing claims for cosmetic products.
FDA Warns JabaLabs About Drug Claims For Anti-Aging Cosmetics
An FDA warning letter to San Antonio, Texas-based skin-care marketer JabaLabs, LLC signals that the agency is continuing its efforts to crack down on overreaching marketing claims for cosmetic products.
Less Tolerant FDA May Flex Enforcement Muscles On Cosmeceuticals - Lawyer
FDA under the new administration may have a sharper eye on cosmeceuticals than it has in years past, according to Georgia C. Ravitz, a food and drug law lawyer at Arendt Fox